Valeant Eyes New Growth Platform With Bausch & Lomb
In the high-stakes M&A game, Valeant Pharmaceuticals CEO Michael Pearson has shown skill in navigating the acquisition trail. Pearson has made more than 50 buyouts since taking the helm in 2008 as he's moved to push the Canadian drugmaker into new markets and build up its product portfolio. Pearson's aggressive acquisition strategy helped Valeant (VRX) nearly quintuple revenue the past four years. Despite the huge growth spurt, Pearson continues
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here